Antibody-Drug Conjugates in Gynecologic Oncology: Advances, Challenges, and Future Directions

Key Points

• Antibody-drug conjugates show potential for enhanced therapeutic efficacy in gynecologic oncology.
• They have been designed to target specific biomarkers, offering a more personalized treatment approach.
• Ongoing challenges include identifying the right targets and managing potential adverse effects.
• Future directions aim to improve treatment outcomes using novel delivery systems and combination therapies.